* pregnancy, breast-feeding or planned pregnancy. * hypersensitivity to ciclesonide or to any of the excipients. * concomitant medication with cortisone, ketoconazole, itraconazole, ritonavir or nelfinavir. * treatment with\> 8 l oxygen / min or supply of \> 50% oxygen with nasal high-flow cannula * ongoing palliative care or expected survival of less than 72 hours. * expected admission to the intensive care unit within 48 hours. * active or inactive pulmonary tuberculosis. * severe liver failure (child-pugh c) * diagnosed with pulmonary arterial hypertension (pah) or fibrosis. * mental inability, reluctance or language difficulties that make it difficult to understand the meaning of participating in the study. * participates in or has recently participated in a clinical trial in the last 30 days. previous participation in this study.

* pregnancy, breast-feeding or planned pregnancy. * hypersensitivity to ciclesonide or to any of the excipients. * concomitant medication with cortisone, ketoconazole, itraconazole, ritonavir or nelfinavir. * treatment with\> 8 l oxygen / min or supply of \> 50% oxygen with nasal high-flow cannula * ongoing palliative care or expected survival of less than 72 hours. * expected admission to the intensive care unit within 48 hours. * active or inactive pulmonary tuberculosis. * severe liver failure (child-pugh c) * diagnosed with pulmonary arterial hypertension (pah) or fibrosis. * mental inability, reluctance or language difficulties that make it difficult to understand the meaning of participating in the study. * participates in or has recently participated in a clinical trial in the last 30 days. previous participation in this study.

pregnancy, breast-feeding or planned pregnancy. hypersensitivity to ciclesonide or to any of the excipients. concomitant medication with cortisone, ketoconazole, itraconazole, ritonavir or nelfinavir. treatment with> 8 l oxygen / min or supply of > 50% oxygen with nasal high-flow cannula ongoing palliative care or expected survival of less than 72 hours. expected admission to the intensive care unit within 48 hours. active or inactive pulmonary tuberculosis. severe liver failure (child-pugh c) diagnosed with pulmonary arterial hypertension (pah) or fibrosis. mental inability, reluctance or language difficulties that make it difficult to understand the meaning of participating in the study. participates in or has recently participated in a clinical trial in the last 30 days. previous participation in this study.

pregnancy, breast-feeding or planned pregnancy. hypersensitivity to ciclesonide or to any of the excipients. concomitant medication with cortisone, ketoconazole, itraconazole, ritonavir or nelfinavir. treatment with> 8 l oxygen / min or supply of > 50% oxygen with nasal high-flow cannula ongoing palliative care or expected survival of less than 72 hours. expected admission to the intensive care unit within 48 hours. active or inactive pulmonary tuberculosis. severe liver failure (child-pugh c) diagnosed with pulmonary arterial hypertension (pah) or fibrosis. mental inability, reluctance or language difficulties that make it difficult to understand the meaning of participating in the study. participates in or has recently participated in a clinical trial in the last 30 days. previous participation in this study.

pregnant or breastfeeding women. history of hypersensitivity to ciclesonide or other substances included in the treatment. ongoing use of corticosteroids, ketokonazol, itrakonazol, ritonavir or nelfinavir. receiving >8 l oxygen/min or >50 % oxygen with nasal high flow therapy. ongoing or planned palliative care or an expected survival of less than 72 h. expected admission to intensive care unit within 48 h. active or inactive pulmonary tuberculosis. severe liver failure (child-pugh c) pulmonary arterial hypertension (pah) or fibrosis. cognitive or physical impairment or insufficient language skills which precludes understanding of information given about the study. participation in a clinical trial within the past 30 days.

pregnant or breastfeeding women. history of hypersensitivity to ciclesonide or other substances included in the treatment. ongoing use of corticosteroids, ketokonazol, itrakonazol, ritonavir or nelfinavir. receiving >8 l oxygen/min or >50 % oxygen with nasal high flow therapy. ongoing or planned palliative care or an expected survival of less than 72 h. expected admission to intensive care unit within 48 h. active or inactive pulmonary tuberculosis. severe liver failure (child-pugh c) pulmonary arterial hypertension (pah) or fibrosis. cognitive or physical impairment or insufficient language skills which precludes understanding of information given about the study. participation in a clinical trial within the past 30 days.

1. pregnant or breastfeeding women. 2. history of hypersensitivity to ciclesonide or other substances included in the treatment. 3. ongoing use of corticosteroids, ketokonazol, itrakonazol, ritonavir or nelfinavir. 4. receiving >8 l oxygen/min or >50 % oxygen with nasal high flow therapy. 5. ongoing or planned palliative care or an expected survival of less than 72 h. 6. expected admission to intensive care unit within 48 h. 7. active or inactive pulmonary tuberculosis. 8. severe liver failure (child-pugh c) 9. pulmonary arterial hypertension (pah) or fibrosis. 10. cognitive or physical impairment or insufficient language skills which precludes understanding of information given about the study. 11. participation in a clinical trial within the past 30 days.

1. pregnant or breastfeeding women. 2. history of hypersensitivity to ciclesonide or other substances included in the treatment. 3. ongoing use of corticosteroids, ketokonazol, itrakonazol, ritonavir or nelfinavir. 4. receiving >8 l oxygen/min or >50 % oxygen with nasal high flow therapy. 5. ongoing or planned palliative care or an expected survival of less than 72 h. 6. expected admission to intensive care unit within 48 h. 7. active or inactive pulmonary tuberculosis. 8. severe liver failure (child-pugh c) 9. pulmonary arterial hypertension (pah) or fibrosis. 10. cognitive or physical impairment or insufficient language skills which precludes understanding of information given about the study. 11. participation in a clinical trial within the past 30 days.